Diagnostic And Prognostic Markers In High-Grade Glioma

Trial Information

Diagnostic And Prognostic Markers In High-Grade Glioma

OBJECTIVES:

- To evaluate the diagnostic and prognostic relevance of various molecular, cytogenetic,
and other tumor markers in high-grade glioma in paraffin-embedded tissue collected from
patients enrolled in the Mayo Clinic or North Central Cancer Treatment Group (NCCTG)
high-grade glioma trials conducted since 1979.

- To evaluate alterations of specific chromosomes and chromosomal regions including 7,
9p, 10p, 10q, 13q, 17p, 17q, 19q, 22q, X, and Y using PCR analysis of microsatellite
repeats and FISH.

- To determine DNA ploidy by flow cytometric analysis.

- To examine various markers of cellular proliferation and cellular function including
flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of
PCNA, Ki-67, and p53.

- To evaluate additional markers identified by the Glioma Markers Network.

- To compare the incidence of markers in the major histologic subtypes (anaplastic
astrocytoma [AA], anaplastic oligoastrocytoma [AOA], glioblastoma multiforme [GBM]) and
to assess their correlation in the total group, as well as within each of these
subtypes.

- To compare the ploidy determinations by FISH and flow cytometry.

OUTLINE: Paraffin-embedded tissue and peripheral blood samples, previously or currently
collected from clinical trials participants at the time she/he enrolled in the trial, are
evaluated for as many markers as possible, changes in cytogenic and molecular genetic tumor
markers, frequency distributions of all tumor markers and histological and clinical
variables by polymerase chain reaction, IHC, flow cytometry, and FISH analysis.